Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification

Yongqi Ding; Yike Jiang; Hong Zeng; Minqin Zhou; Xuanrui Zhou; Zichuan Yu; Jingying Pan; Xitong Geng; Yanting Zhu; Hao Zheng; Shuhan Huang; Yiyang Gong; Huabin Huang; Chengfeng Xiong; Da Huang

doi:doi:10.18632/aging.205736

← Back

Research Paper Volume 16, Issue 8 pp 6954—6989

Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification

Figure 3. Relationship between LAPTM4A and prognosis of glioma patients. LGG patients with higher expression levels of LAPTM4A had unfavorable (A) OS, (B) DSS, and (C) PFS. GBMLGG patients with higher expression levels of LAPTM4A had awful (D) OS, (E) DSS, and (F) PFS. GBM patients with higher expression levels of LAPTM4A had undesirable (G) OS, (H) DSS, and (I) PFS.